Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JY09 versus dulaglutide in type 2 diabetes inadequately controlled by metformin
NCT06257966Phase 3Active, not recruiting
- Sponsor
- Beijing Dongfang Biotech Co., Ltd.
- Start
- Jul 2024
- Primary completion
- Oct 2026
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 3 trial of JY-09 in type 2 diabetes mellitus (T2DM), sponsored by Beijing Dongfang Biotech Co., Ltd.. Started Jul 2024; status: active, not recruiting.
02
Drugs
JY-09
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06257966.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06257966.